Skip to content

A prospective, split-face, single-blinded, randomized controlled clinical trial of Alexandrite 755 nm Picosecond Laser With Diffractive Lens Array for facial photoaging

A prospective, split-face, single-blinded, randomized controlled clinical trial of Alexandrite 755 nm Picosecond Laser With Diffractive Lens Array for facial photoaging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095652
Enrollment
Unknown
Registered
2025-01-10
Start date
2025-01-17
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Photoaging

Interventions

Blank control side:No treatment
Picosure Pro laser treatment side:PicoSure Pro Platinum Focus Fractional Laser Treatment

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 according with the indication of facial skin aging patients 40-65 years old (including 40 and 65 years old) , male and female are not limited; 2 the clinical diagnosis is clear, fitzpatrick Type III-V healthy subjects with previously untreated facial photoaging (facial wrinkles, macropores, wrinkles around eyes and lips, and/or pigmentation); 3.the subjects agreed not to undergo any operation or treatment of facial dermatosis except the experimental treatment during the period of treatment and observation; 4 patients without obvious asymmetry of photoaging on the left and right face; 5 after knowing the treatment plan and risk, I or the Guardian signed the informed consent voluntarily, willing to accept the self-controlled trial, and cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1.logo A pregnant woman or a woman with a planned pregnancy; 2 allergy to surface disinfectant; 3 patients with facial wound or skin ulcer; 4 patients with severe organic diseases or mental disorders; 5 patients who are participating in other clinical trials; 6 subjects who had received laser or energy therapy, cosmetic surgery (such as filling, injection, plastic surgery) and/or chemical stripping therapy in the past 1 year; 7 subjects with a history of impaired healing or scarring; 8 patients with Chloasma on the face.

Design outcomes

Primary

MeasureTime frame
logo Light aging scale;

Secondary

MeasureTime frame
Degree of facial rejuvenation;3D imaging;Visia imaging;Safety evaluation;

Countries

China

Contacts

Public ContactZhen Zhang

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

zz6503@vip.126.com+86 21 23271699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026